Litcius/Paper detail

Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam

Naphat Satapoomin, Punyawee Dulyayangkul, Matthew B. Avison

2022Antimicrobial Agents and Chemotherapy26 citationsDOIOpen Access PDF

Abstract

We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has a ramR plus ompK36 mutation, and produces the V239G variant KPC-3 (V240G per the standard numbering system) exhibits resistance to ceftazidime-avibactam plus aztreonam and imipenem-relebactam but not cefepime-taniborbactam. The V239G variant does not generate collateral β-lactam susceptibility like many KPC-3 variants associated with ceftazidime-avibactam resistance.

Topics & Concepts

AztreonamCefepimeKlebsiella pneumoniaeMicrobiologyMeropenemCeftazidime/avibactamCeftazidimeBiologyImipenemMedicineAntibioticsBacteriaAntibiotic resistanceGeneticsEscherichia coliPseudomonas aeruginosaGeneAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyInfections and bacterial resistance